Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | NOS2 | P35228 | 3/20 | 0.49 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8229301 | 1.00 | NOS3 (0.49) | NOS3NOS1NOS2SLC1A5SLC7A5 | |
| SCHEMBL12662808 | 0.84 | TSHR (0.39) | NOS3NOS1NOS2TSHR | |
| SCHEMBL10187395 | 0.83 | TSHR (0.59) | NOS3NOS1NOS2SLC1A5SLC7A5 | |
| SCHEMBL1231993 | 0.83 | TSHR (0.59) | NOS3NOS1NOS2SLC1A5SLC7A5 | |
| SCHEMBL770416 | 0.82 | NOS3 (0.56) | NOS3NOS1NOS2SLC1A5SLC7A5 | |
| SCHEMBL9980878 | 0.82 | NOS3 (0.56) | NOS3NOS1NOS2SLC1A5SLC7A5 | |
| SCHEMBL770417 | 0.82 | NOS3 (0.56) | NOS3NOS1NOS2SLC1A5SLC7A5 | |
| SCHEMBL598363 | 0.82 | NOS3 (0.56) | NOS3NOS1NOS2SLC1A5SLC7A5 | |
| Hydrogen Sulfide SCHEMBL22463012 | 0.80 | NOS3 (0.55) | NOS3NOS1NOS2SLC1A5SLC7A5 | |
| Hydrochloric Acid SCHEMBL19209653 | 0.80 | NOS1 (0.55) | NOS3NOS1NOS2SLC1A5SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518989-B2 | Prodrugs of short-chain fatty acids and treatment methods | GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2013-08-27 | — | — | US | claimed |
| US-20110245339-A1 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC (US) | 2011-10-06 | — | — | US | claimed |
| US-20090123388-A1 | Prodrugs of Short-Chain Fatty Acids and Treatment Methods | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-05-14 | — | — | US | claimed |
| WO-2006076734-A2 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2006-07-20 | — | — | WO | claimed |
| WO-2024123101-A1 | MICROORGANISM PRODUCING PURINE NUCLEOTIDE, AND METHOD FOR PRODUCING PURINE NUCLEOTIDE USING SAME | 씨제이제일제당 (주) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123108-A1 | PURINE NUCLEOTIDE-PRODUCING MICROORGANISM AND METHOD FOR PRODUCTION OF PURINE NUCLEOTIDE USING SAME | 씨제이제일제당 (주) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123109-A1 | MICROORGANISM PRODUCING PURINE NUCLEOTIDES AND METHOD FOR PRODUCING PURINE NUCLEOTIDES USING SAME | 씨제이제일제당 (주) | 2024-06-13 | — | — | WO | disclosed |
| US-20230201226-A1 | COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| EP-3426766-B1 | METHOD FOR CONTINUOUS BIOSENSING | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIV OF JERUSALEM LTD (IL) | 2022-12-28 | — | — | EP | disclosed |
| US-20220348935-A1 | NOVEL GENETICALLY ENGINEERED MICROORGANISM CAPABLE OF GROWING ON FORMATE, METHANOL, METHANE OR CO2 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-11-03 | — | — | US | disclosed |
| US-20210379094-A1 | METHOD FOR REDUCING DRUG-INDUCED NEPHROTOXICITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-12-09 | — | — | US | disclosed |
| US-20190086391-A1 | METHOD AND SYSTEM FOR CONTINUOUS BIOSENSING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-03-21 | — | — | US | disclosed |
| EP-2434421-A2 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | The Regents of The University of California (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110245339-A1 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110158980-A1 | METHODS TO TREAT AND SCREEN FOR AGENTS TO TREAT OBESITY | TRUSTEES OF TUFTS COLLEGE (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010019434-A1 | METHODS TO TREAT AND SCREEN FOR AGENTS TO TREAT OBESITY | TRUSTEES OF TUFTS COLLEGE (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20090123388-A1 | Prodrugs of Short-Chain Fatty Acids and Treatment Methods | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-05-14 | — | — | US | disclosed |
| US-7312049-B2 | Total amino acid stabilization during cell-free protein synthesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070004001-A1 | Total amino acid stabilization during cell-free protein synthesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2007-01-04 | — | — | US | disclosed |
| WO-2006076734-A2 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123388-A1 | Prodrugs of Short-Chain Fatty Acids and Treatment Methods | SLC1A5, SPTSSB, SLC27A1 | NOS3 836/4885NOS1 902/4885NOS2 840/4885 |
| US-20110245339-A1 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | SLC1A5, SPTSSB, SLC27A1 | NOS3 836/4885NOS1 902/4885NOS2 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.